178 related articles for article (PubMed ID: 29594016)
1. Head-to-head comparison of prostate cancer risk calculators predicting biopsy outcome.
Pereira-Azevedo N; Verbeek JFM; Nieboer D; Bangma CH; Roobol MJ
Transl Androl Urol; 2018 Feb; 7(1):18-26. PubMed ID: 29594016
[TBL] [Abstract][Full Text] [Related]
2. Reducing prostate biopsies and magnetic resonance imaging with prostate cancer risk stratification.
Davik P; Remmers S; Elschot M; Roobol MJ; Bathen TF; Bertilsson H
BJUI Compass; 2022 Sep; 3(5):344-353. PubMed ID: 35950035
[TBL] [Abstract][Full Text] [Related]
3. Does Multiparametric Magnetic Resonance of Prostate Outperform Risk Calculators in Predicting Prostate Cancer in Biopsy Naïve Patients?
Falagario UG; Silecchia G; Bruno SM; Di Nauta M; Auciello M; Sanguedolce F; Milillo P; Macarini L; Selvaggio O; Carrieri G; Cormio L
Front Oncol; 2020; 10():603384. PubMed ID: 33489907
[TBL] [Abstract][Full Text] [Related]
4. Incorporating PHI in decision making: external validation of the Rotterdam risk calculators for detection of prostate cancer.
Rius Bilbao L; Aguirre Larracoechea U; Valladares Gomez C; Remmers S; Mar Medina C;
World J Urol; 2024 Mar; 42(1):141. PubMed ID: 38478041
[TBL] [Abstract][Full Text] [Related]
5. Head-to-head Comparison of Conventional, and Image- and Biomarker-based Prostate Cancer Risk Calculators.
Mortezavi A; Palsdottir T; Eklund M; Chellappa V; Murugan SK; Saba K; Ankerst DP; Haug ES; Nordström T
Eur Urol Focus; 2021 May; 7(3):546-553. PubMed ID: 32451315
[TBL] [Abstract][Full Text] [Related]
6. External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort.
Chandra Engel J; Palsdottir T; Ankerst D; Remmers S; Mortezavi A; Chellappa V; Egevad L; Grönberg H; Eklund M; Nordström T
Eur Urol Open Sci; 2022 Jul; 41():1-7. PubMed ID: 35813248
[TBL] [Abstract][Full Text] [Related]
7. External validation of two mpMRI-risk calculators predicting risk of prostate cancer before biopsy.
Pallauf M; Steinkohl F; Zimmermann G; Horetzky M; Rajwa P; Pradere B; Lindner AK; Pichler R; Kunit T; Shariat SF; Lusuardi L; Drerup M
World J Urol; 2022 Oct; 40(10):2451-2457. PubMed ID: 35941246
[TBL] [Abstract][Full Text] [Related]
8. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
[TBL] [Abstract][Full Text] [Related]
9. Observational study comparing the accuracy/variability between the ERSPC and the PCPT risk calculators for the prediction of significant prostate cancer in patients with PSA <10 ng/mL.
Gomez Gomez E; Salamanca Bustos JJ; Carrasco Valiente J; Fernandez Rueda JL; Blanca A; Valero Rosa J; Bravo Arrebola I; Marquez López J; Jimenez Vacas JM; Luque R; Requena Tapia MJ
BMJ Open; 2019 Nov; 9(11):e031032. PubMed ID: 31722940
[TBL] [Abstract][Full Text] [Related]
10. The Mount Sinai Prebiopsy Risk Calculator for Predicting any Prostate Cancer and Clinically Significant Prostate Cancer: Development of a Risk Predictive Tool and Validation with Advanced Neural Networking, Prostate Magnetic Resonance Imaging Outcome Database, and European Randomized Study of Screening for Prostate Cancer Risk Calculator.
Parekh S; Ratnani P; Falagario U; Lundon D; Kewlani D; Nasri J; Dovey Z; Stroumbakis D; Ranti D; Grauer R; Sobotka S; Pedraza A; Wagaskar V; Mistry L; Jambor I; Lantz A; Ettala O; Stabile A; Taimen P; Aronen HJ; Knaapila J; Perez IM; Gandaglia G; Martini A; Picker W; Haug E; Cormio L; Nordström T; Briganti A; Boström PJ; Carrieri G; Haines K; Gorin MA; Wiklund P; Menon M; Tewari A
Eur Urol Open Sci; 2022 Jul; 41():45-54. PubMed ID: 35813258
[TBL] [Abstract][Full Text] [Related]
11. Prostate cancer risk prediction using the novel versions of the European Randomised Study for Screening of Prostate Cancer (ERSPC) and Prostate Cancer Prevention Trial (PCPT) risk calculators: independent validation and comparison in a contemporary European cohort.
Poyet C; Nieboer D; Bhindi B; Kulkarni GS; Wiederkehr C; Wettstein MS; Largo R; Wild P; Sulser T; Hermanns T
BJU Int; 2016 Mar; 117(3):401-8. PubMed ID: 26332503
[TBL] [Abstract][Full Text] [Related]
12. Comparison of risk calculators from the Prostate Cancer Prevention Trial and the European Randomized Study of Screening for Prostate Cancer in a contemporary Canadian cohort.
Trottier G; Roobol MJ; Lawrentschuk N; Boström PJ; Fernandes KA; Finelli A; Chadwick K; Evans A; van der Kwast TH; Toi A; Zlotta AR; Fleshner NE
BJU Int; 2011 Oct; 108(8 Pt 2):E237-44. PubMed ID: 21507190
[TBL] [Abstract][Full Text] [Related]
13. How to make clinical decisions to avoid unnecessary prostate screening in biopsy-naïve men with PI-RADs v2 score ≤ 3?
Zhang Y; Zeng N; Zhang F; Huang Y; Tian Y
Int J Clin Oncol; 2020 Jan; 25(1):175-186. PubMed ID: 31473884
[TBL] [Abstract][Full Text] [Related]
14. Prediction of prostate cancer risk: the role of prostate volume and digital rectal examination in the ERSPC risk calculators.
Roobol MJ; van Vugt HA; Loeb S; Zhu X; Bul M; Bangma CH; van Leenders AG; Steyerberg EW; Schröder FH
Eur Urol; 2012 Mar; 61(3):577-83. PubMed ID: 22104592
[TBL] [Abstract][Full Text] [Related]
15. European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study.
Foley RW; Maweni RM; Gorman L; Murphy K; Lundon DJ; Durkan G; Power R; O'Brien F; O'Malley KJ; Galvin DJ; Brendan Murphy T; William Watson R
BJU Int; 2016 Nov; 118(5):706-713. PubMed ID: 26833820
[TBL] [Abstract][Full Text] [Related]
16. Do prostate cancer risk models improve the predictive accuracy of PSA screening? A meta-analysis.
Louie KS; Seigneurin A; Cathcart P; Sasieni P
Ann Oncol; 2015 May; 26(5):848-864. PubMed ID: 25403590
[TBL] [Abstract][Full Text] [Related]
17. Combined Clinical Parameters and Multiparametric Magnetic Resonance Imaging for Advanced Risk Modeling of Prostate Cancer-Patient-tailored Risk Stratification Can Reduce Unnecessary Biopsies.
Radtke JP; Wiesenfarth M; Kesch C; Freitag MT; Alt CD; Celik K; Distler F; Roth W; Wieczorek K; Stock C; Duensing S; Roethke MC; Teber D; Schlemmer HP; Hohenfellner M; Bonekamp D; Hadaschik BA
Eur Urol; 2017 Dec; 72(6):888-896. PubMed ID: 28400169
[TBL] [Abstract][Full Text] [Related]
18. Performance of magnetic resonance imaging-based prostate cancer risk calculators and decision strategies in two large European medical centres.
Davik P; Remmers S; Elschot M; Roobol MJ; Bathen TF; Bertilsson H
BJU Int; 2024 Mar; 133(3):278-288. PubMed ID: 37607322
[TBL] [Abstract][Full Text] [Related]
19. Prediction of Prostate Cancer: External Validation of the ERSPC Risk Calculator in a Contemporary Dutch Clinical Cohort.
Gayet M; Mannaerts CK; Nieboer D; Beerlage HP; Wijkstra H; Mulders PFA; Roobol MJ
Eur Urol Focus; 2018 Mar; 4(2):228-234. PubMed ID: 28753781
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Magnetic Resonance Imaging-Based Risk Calculators to Predict Prostate Cancer Risk.
Patel HD; Remmers S; Ellis JL; Li EV; Roobol MJ; Fang AM; Davik P; Rais-Bahrami S; Murphy AB; Ross AE; Gupta GN
JAMA Netw Open; 2024 Mar; 7(3):e241516. PubMed ID: 38451522
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
